dr. derakhshandeh, phd mutation screening 2 quantitative pcr and dosage
TRANSCRIPT
![Page 1: Dr. Derakhshandeh, PhD Mutation Screening 2 Quantitative PCR and Dosage](https://reader031.vdocument.in/reader031/viewer/2022032203/56649e0c5503460f94af5ca8/html5/thumbnails/1.jpg)
Dr. Derakhshandeh, PhD
Mutation ScreeningMutation Screening
![Page 2: Dr. Derakhshandeh, PhD Mutation Screening 2 Quantitative PCR and Dosage](https://reader031.vdocument.in/reader031/viewer/2022032203/56649e0c5503460f94af5ca8/html5/thumbnails/2.jpg)
2
Quantitative PCR and Dosage
![Page 3: Dr. Derakhshandeh, PhD Mutation Screening 2 Quantitative PCR and Dosage](https://reader031.vdocument.in/reader031/viewer/2022032203/56649e0c5503460f94af5ca8/html5/thumbnails/3.jpg)
3
Quantitative PCR and Dosage
used in a number of diagnostic applications eg. SMA trisomy 21 X-linked
Agammaglobulinemia
![Page 4: Dr. Derakhshandeh, PhD Mutation Screening 2 Quantitative PCR and Dosage](https://reader031.vdocument.in/reader031/viewer/2022032203/56649e0c5503460f94af5ca8/html5/thumbnails/4.jpg)
4
SMA
![Page 5: Dr. Derakhshandeh, PhD Mutation Screening 2 Quantitative PCR and Dosage](https://reader031.vdocument.in/reader031/viewer/2022032203/56649e0c5503460f94af5ca8/html5/thumbnails/5.jpg)
5
CLASSIFICATIONSMA TYPE I
(Werdnig-Hoffmann)
SMA TYPE II (Classic)
SMA TYPE III (Kugelberg-Welander)
![Page 6: Dr. Derakhshandeh, PhD Mutation Screening 2 Quantitative PCR and Dosage](https://reader031.vdocument.in/reader031/viewer/2022032203/56649e0c5503460f94af5ca8/html5/thumbnails/6.jpg)
6
SMA TYPE I
Severe form of SMA
Onset : first 6 months
Death : < 2 year
Never raising the head or sitting
![Page 7: Dr. Derakhshandeh, PhD Mutation Screening 2 Quantitative PCR and Dosage](https://reader031.vdocument.in/reader031/viewer/2022032203/56649e0c5503460f94af5ca8/html5/thumbnails/7.jpg)
7
SMA TYPE I
![Page 8: Dr. Derakhshandeh, PhD Mutation Screening 2 Quantitative PCR and Dosage](https://reader031.vdocument.in/reader031/viewer/2022032203/56649e0c5503460f94af5ca8/html5/thumbnails/8.jpg)
8
SMA TYPE II
Less severe
Clinical appearing : < 18 months
Able to sit un aid
Death : about 9 years
![Page 9: Dr. Derakhshandeh, PhD Mutation Screening 2 Quantitative PCR and Dosage](https://reader031.vdocument.in/reader031/viewer/2022032203/56649e0c5503460f94af5ca8/html5/thumbnails/9.jpg)
9
SMA TYPE III
Mildest form of SMA
Onset : > 18 months
Walking without aid
![Page 10: Dr. Derakhshandeh, PhD Mutation Screening 2 Quantitative PCR and Dosage](https://reader031.vdocument.in/reader031/viewer/2022032203/56649e0c5503460f94af5ca8/html5/thumbnails/10.jpg)
10
GENETIC MAP
Three candidate genes named SMN (Survival Motor Neuron), NAIP (Neuronal Apoptosis Inhibitory Protein) and P44 were identified in this locus
Up to 95% of SMA patients (SMNI-III) are homozygously deleted for two exons (7&8) of both telomeric copy of SMN gene (SMNt)
![Page 11: Dr. Derakhshandeh, PhD Mutation Screening 2 Quantitative PCR and Dosage](https://reader031.vdocument.in/reader031/viewer/2022032203/56649e0c5503460f94af5ca8/html5/thumbnails/11.jpg)
11
Deletions
Up to 5% of SMA patients have frameshift mutations, gene conversions and point mutation
Exons 5 and 6 of NAIPt gene are deleted in approximately 50% of type I SMA and 18% of types II and III SMA
P44t is lacked or intrrupted in 73%
of SMA type I patients and 7% in types II and III
![Page 12: Dr. Derakhshandeh, PhD Mutation Screening 2 Quantitative PCR and Dosage](https://reader031.vdocument.in/reader031/viewer/2022032203/56649e0c5503460f94af5ca8/html5/thumbnails/12.jpg)
12
The summery of normal alleles (N) , mutant alleles (M) and deletion types (D) of SMN
![Page 13: Dr. Derakhshandeh, PhD Mutation Screening 2 Quantitative PCR and Dosage](https://reader031.vdocument.in/reader031/viewer/2022032203/56649e0c5503460f94af5ca8/html5/thumbnails/13.jpg)
13
MOLECULAR DIAGNOSIS & PND
PCR-SSCP or PCR-RFLP of SMN gene enables confirmation of a suspected clinical diagnosis of SMA or prenatal diagnosis
These two techniques based on nucleotide differences of both exon 7 and exon 8 of telomeric and centromeric copy of SMN
![Page 14: Dr. Derakhshandeh, PhD Mutation Screening 2 Quantitative PCR and Dosage](https://reader031.vdocument.in/reader031/viewer/2022032203/56649e0c5503460f94af5ca8/html5/thumbnails/14.jpg)
14
![Page 15: Dr. Derakhshandeh, PhD Mutation Screening 2 Quantitative PCR and Dosage](https://reader031.vdocument.in/reader031/viewer/2022032203/56649e0c5503460f94af5ca8/html5/thumbnails/15.jpg)
15
![Page 16: Dr. Derakhshandeh, PhD Mutation Screening 2 Quantitative PCR and Dosage](https://reader031.vdocument.in/reader031/viewer/2022032203/56649e0c5503460f94af5ca8/html5/thumbnails/16.jpg)
16
![Page 17: Dr. Derakhshandeh, PhD Mutation Screening 2 Quantitative PCR and Dosage](https://reader031.vdocument.in/reader031/viewer/2022032203/56649e0c5503460f94af5ca8/html5/thumbnails/17.jpg)
17
![Page 18: Dr. Derakhshandeh, PhD Mutation Screening 2 Quantitative PCR and Dosage](https://reader031.vdocument.in/reader031/viewer/2022032203/56649e0c5503460f94af5ca8/html5/thumbnails/18.jpg)
18
![Page 19: Dr. Derakhshandeh, PhD Mutation Screening 2 Quantitative PCR and Dosage](https://reader031.vdocument.in/reader031/viewer/2022032203/56649e0c5503460f94af5ca8/html5/thumbnails/19.jpg)
19
Deletion Analysis of SMN gene
• Exones 7 and 8 of SMN gene were amplified and cut by Dra I and Dde I , respectively. (only centromeric copy is cutted)
• Absence of SMNt exone(s) 7 (and 8) confirm diagnosis of SMA
![Page 20: Dr. Derakhshandeh, PhD Mutation Screening 2 Quantitative PCR and Dosage](https://reader031.vdocument.in/reader031/viewer/2022032203/56649e0c5503460f94af5ca8/html5/thumbnails/20.jpg)
20
![Page 21: Dr. Derakhshandeh, PhD Mutation Screening 2 Quantitative PCR and Dosage](https://reader031.vdocument.in/reader031/viewer/2022032203/56649e0c5503460f94af5ca8/html5/thumbnails/21.jpg)
21
188 bp
164 bp
188 bp
123 bp
65 bp
Exon 7, DraI
Exon 8, DdeI
![Page 22: Dr. Derakhshandeh, PhD Mutation Screening 2 Quantitative PCR and Dosage](https://reader031.vdocument.in/reader031/viewer/2022032203/56649e0c5503460f94af5ca8/html5/thumbnails/22.jpg)
22
SMN Deletion AnalysisDerakhshande et al.
(Farhud Genetic Lab/ NRCGEB)
• SMNt Exon 7 is deleted in affected child
![Page 23: Dr. Derakhshandeh, PhD Mutation Screening 2 Quantitative PCR and Dosage](https://reader031.vdocument.in/reader031/viewer/2022032203/56649e0c5503460f94af5ca8/html5/thumbnails/23.jpg)
23
NAIP Gene Deletion Analysis
• Exones 5 & 6 of NAIP gene were amplified with exon 13 which was the internal control
• Absence of exon 5 and exon 6 ( which only exist within the telomeric functional copy of NAIP) was detected in ~50% of type I SMA and 18% of types II and III SMA
![Page 24: Dr. Derakhshandeh, PhD Mutation Screening 2 Quantitative PCR and Dosage](https://reader031.vdocument.in/reader031/viewer/2022032203/56649e0c5503460f94af5ca8/html5/thumbnails/24.jpg)
24
NAIP Deletion analysisDerakhshande et al.
(Farhud Genetic Lab/ NRCGEB)
![Page 25: Dr. Derakhshandeh, PhD Mutation Screening 2 Quantitative PCR and Dosage](https://reader031.vdocument.in/reader031/viewer/2022032203/56649e0c5503460f94af5ca8/html5/thumbnails/25.jpg)
25
![Page 26: Dr. Derakhshandeh, PhD Mutation Screening 2 Quantitative PCR and Dosage](https://reader031.vdocument.in/reader031/viewer/2022032203/56649e0c5503460f94af5ca8/html5/thumbnails/26.jpg)
26
• The objective of this study was to genetically characterize the childhood onset spinal muscular
atrophy in Iran.
SMN NAIP
Deletion of exon 7 & 8
Deletion of exon 5 & 6
SMA type I (n=70) 70(100%) 61(87%)
SMA type II (n=3) 2(66%) 1(33%)
SMA type III (n=2) 1(50%) 0(0%)
![Page 27: Dr. Derakhshandeh, PhD Mutation Screening 2 Quantitative PCR and Dosage](https://reader031.vdocument.in/reader031/viewer/2022032203/56649e0c5503460f94af5ca8/html5/thumbnails/27.jpg)
27
• Various deletion haplotypes were constructed by using genotypes of SMN and NAIP genes.
• Haplotype A, which has the deletions of all two involved genes, were deleted in approximately 83% of type I and II SMA but not in type III and was found predominantly in the severe group with an early onset at less than 6 month of age.
• we report Thirty four our experiences for prenatal diagnosis
Haplotypes (%)
A B C
SMA type I (n=70)
87 100 0
SMA type II (n=3)
33 66 33
SMA type III (n=2)
0 50 50
![Page 28: Dr. Derakhshandeh, PhD Mutation Screening 2 Quantitative PCR and Dosage](https://reader031.vdocument.in/reader031/viewer/2022032203/56649e0c5503460f94af5ca8/html5/thumbnails/28.jpg)
28
• These studies suggested that the frequency of gene deletions of SMN1 and NAIP gene is a few higher than previous reports. It is may be due to high rate of consanguine marriage by Iranian Muslims (96 % in this families). Thus, the conformation of SMA related gene deletion will also be a useful tool for the pre and postnatal diagnostic. In addition to common PCR methods for SMN exon 7 and 8 and NAIP exons 4 and 5, we also conducted multiplex PCR of exon 5, 6 and 13 of the NAIP telomere in one reaction.
![Page 29: Dr. Derakhshandeh, PhD Mutation Screening 2 Quantitative PCR and Dosage](https://reader031.vdocument.in/reader031/viewer/2022032203/56649e0c5503460f94af5ca8/html5/thumbnails/29.jpg)
29
Quantitative PCR and Dosage
• Products can be measured by image scanning of agarose gels or Polaroid pictures
• Method is not sensitive to template concentration (1.3g to 2.7pg DNA used) but can be affected by template quality so preparation is important.
![Page 30: Dr. Derakhshandeh, PhD Mutation Screening 2 Quantitative PCR and Dosage](https://reader031.vdocument.in/reader031/viewer/2022032203/56649e0c5503460f94af5ca8/html5/thumbnails/30.jpg)
30
More complex methodSMA
This method allows quantitation of the copy number of SMNT and SMNC genes on chromosome 5q12
![Page 31: Dr. Derakhshandeh, PhD Mutation Screening 2 Quantitative PCR and Dosage](https://reader031.vdocument.in/reader031/viewer/2022032203/56649e0c5503460f94af5ca8/html5/thumbnails/31.jpg)
31
The homologous gene quantitative polymerase chain reaction(HGQ-PCR)
![Page 32: Dr. Derakhshandeh, PhD Mutation Screening 2 Quantitative PCR and Dosage](https://reader031.vdocument.in/reader031/viewer/2022032203/56649e0c5503460f94af5ca8/html5/thumbnails/32.jpg)
32
Detection of trisomy 21 by HGQ-PCRLanes 1–16 Serial dilutions for a normal individual and aDown’s syndrome patient used to evaluate
the optimal HGQPCR
![Page 33: Dr. Derakhshandeh, PhD Mutation Screening 2 Quantitative PCR and Dosage](https://reader031.vdocument.in/reader031/viewer/2022032203/56649e0c5503460f94af5ca8/html5/thumbnails/33.jpg)
33
SequencingSequencing
![Page 34: Dr. Derakhshandeh, PhD Mutation Screening 2 Quantitative PCR and Dosage](https://reader031.vdocument.in/reader031/viewer/2022032203/56649e0c5503460f94af5ca8/html5/thumbnails/34.jpg)
34
Top and bottom strand differences for a point
mutation
![Page 35: Dr. Derakhshandeh, PhD Mutation Screening 2 Quantitative PCR and Dosage](https://reader031.vdocument.in/reader031/viewer/2022032203/56649e0c5503460f94af5ca8/html5/thumbnails/35.jpg)
35
Top and bottom strand differences for a heterozygous
base
(Click for full size image)
Figure 2. Top and bottom strand differences for a heterozygous base
![Page 36: Dr. Derakhshandeh, PhD Mutation Screening 2 Quantitative PCR and Dosage](https://reader031.vdocument.in/reader031/viewer/2022032203/56649e0c5503460f94af5ca8/html5/thumbnails/36.jpg)
36
Sequencing
![Page 37: Dr. Derakhshandeh, PhD Mutation Screening 2 Quantitative PCR and Dosage](https://reader031.vdocument.in/reader031/viewer/2022032203/56649e0c5503460f94af5ca8/html5/thumbnails/37.jpg)
37
Forensics
![Page 38: Dr. Derakhshandeh, PhD Mutation Screening 2 Quantitative PCR and Dosage](https://reader031.vdocument.in/reader031/viewer/2022032203/56649e0c5503460f94af5ca8/html5/thumbnails/38.jpg)
38
ForensicsPCR analysis PCR
(polymerase chain reaction)RFLP analysisSTR analysis Short tandem
repeat (STR) technology is a forensic analysis
For example, the likelihood that any two individuals (except identical twins) will have the same 13-loci DNA profile can be as high as 1 in 1 billion or greater.
![Page 39: Dr. Derakhshandeh, PhD Mutation Screening 2 Quantitative PCR and Dosage](https://reader031.vdocument.in/reader031/viewer/2022032203/56649e0c5503460f94af5ca8/html5/thumbnails/39.jpg)
39
ForensicsMitochondrial DNA Analysis
Mitochondrial DNA analysis (mtDNA) can be used to examine the DNA from samples that cannot be analyzed by RFLP or STR
Nuclear DNA must be extracted from samples for use in RFLP, PCR, and STR
mtDNA analysis uses DNA extracted from another cellular organelle called a mitochondrion
![Page 40: Dr. Derakhshandeh, PhD Mutation Screening 2 Quantitative PCR and Dosage](https://reader031.vdocument.in/reader031/viewer/2022032203/56649e0c5503460f94af5ca8/html5/thumbnails/40.jpg)
40
ForensicsWhile older biological samples that
lack nucleated cellular material, such as hair, bones, and teeth, cannot be analyzed with STR and RFLP
they can be analyzed with mtDNAIn the investigation of cases that
have gone unsolved for many years, mtDNA is extremely valuable.
![Page 41: Dr. Derakhshandeh, PhD Mutation Screening 2 Quantitative PCR and Dosage](https://reader031.vdocument.in/reader031/viewer/2022032203/56649e0c5503460f94af5ca8/html5/thumbnails/41.jpg)
41
ForensicsY-Chromosome Analysis
The Y chromosome is passed directly from father to son
so the analysis of genetic markers on the Y chromosome is especially useful for tracing relationships among males
this technique can be very valuable if the laboratory detects complex mixtures (multiple male contributors)
![Page 42: Dr. Derakhshandeh, PhD Mutation Screening 2 Quantitative PCR and Dosage](https://reader031.vdocument.in/reader031/viewer/2022032203/56649e0c5503460f94af5ca8/html5/thumbnails/42.jpg)
Reverse Dot Blot for Human Mutation
Detection
![Page 43: Dr. Derakhshandeh, PhD Mutation Screening 2 Quantitative PCR and Dosage](https://reader031.vdocument.in/reader031/viewer/2022032203/56649e0c5503460f94af5ca8/html5/thumbnails/43.jpg)
43
Introduction
• Reverse dot blot (RDB)• or reverse allele specific
oligonucleotide (Reverse ASO)
• hybridization • important method for
genotyping common human mutations
![Page 44: Dr. Derakhshandeh, PhD Mutation Screening 2 Quantitative PCR and Dosage](https://reader031.vdocument.in/reader031/viewer/2022032203/56649e0c5503460f94af5ca8/html5/thumbnails/44.jpg)
44
Commonly used in:
• a high mutation spectrum• high frequency disorders
such as:– cystic fibrosis– hemoglobin C (HbC)– hemoglobin E (HbE)– hemoglobin S (HbS)– ß-thalassemias
![Page 45: Dr. Derakhshandeh, PhD Mutation Screening 2 Quantitative PCR and Dosage](https://reader031.vdocument.in/reader031/viewer/2022032203/56649e0c5503460f94af5ca8/html5/thumbnails/45.jpg)
45
Location of mutations in the -globin gene
![Page 46: Dr. Derakhshandeh, PhD Mutation Screening 2 Quantitative PCR and Dosage](https://reader031.vdocument.in/reader031/viewer/2022032203/56649e0c5503460f94af5ca8/html5/thumbnails/46.jpg)
46
RDB procedure
• exons (or other regions of interest)
• amplified by the polymerase chain reaction (PCR)
• using labeled oligonucleotide primers
• 5' biotin label on PCR primers
![Page 47: Dr. Derakhshandeh, PhD Mutation Screening 2 Quantitative PCR and Dosage](https://reader031.vdocument.in/reader031/viewer/2022032203/56649e0c5503460f94af5ca8/html5/thumbnails/47.jpg)
47
Amplicons• Amplification products• denatured • hybridized
– with mutation specific DNA probes
• covalently bound to solid membran
![Page 48: Dr. Derakhshandeh, PhD Mutation Screening 2 Quantitative PCR and Dosage](https://reader031.vdocument.in/reader031/viewer/2022032203/56649e0c5503460f94af5ca8/html5/thumbnails/48.jpg)
48
Incubation• nucleic acids: incubated
with an enzyme conjugated to streptavidin.
• enzyme-conjugated, streptavidin-biotin-nucleic acid complex is then washed
• incubated with– a chromogenic – or luminogenic substrate,
which allows visualization of hybridized spots
![Page 49: Dr. Derakhshandeh, PhD Mutation Screening 2 Quantitative PCR and Dosage](https://reader031.vdocument.in/reader031/viewer/2022032203/56649e0c5503460f94af5ca8/html5/thumbnails/49.jpg)
49
Materials and Methods
• Total genomic DNA• extracted from peripheral
blood leukocytes • Amniotic fluid cells (AF)• chorionic villi (CVS)
![Page 50: Dr. Derakhshandeh, PhD Mutation Screening 2 Quantitative PCR and Dosage](https://reader031.vdocument.in/reader031/viewer/2022032203/56649e0c5503460f94af5ca8/html5/thumbnails/50.jpg)
50
A woman having amniocentesis
![Page 51: Dr. Derakhshandeh, PhD Mutation Screening 2 Quantitative PCR and Dosage](https://reader031.vdocument.in/reader031/viewer/2022032203/56649e0c5503460f94af5ca8/html5/thumbnails/51.jpg)
51
Oligonucleotide probes
• A C6-amino-link phosphoramidite • amino moiety on the 5' end of the
product
![Page 52: Dr. Derakhshandeh, PhD Mutation Screening 2 Quantitative PCR and Dosage](https://reader031.vdocument.in/reader031/viewer/2022032203/56649e0c5503460f94af5ca8/html5/thumbnails/52.jpg)
52
Oligonucleotides used for reverse dot blot (RDB)
![Page 53: Dr. Derakhshandeh, PhD Mutation Screening 2 Quantitative PCR and Dosage](https://reader031.vdocument.in/reader031/viewer/2022032203/56649e0c5503460f94af5ca8/html5/thumbnails/53.jpg)
53RDB
![Page 54: Dr. Derakhshandeh, PhD Mutation Screening 2 Quantitative PCR and Dosage](https://reader031.vdocument.in/reader031/viewer/2022032203/56649e0c5503460f94af5ca8/html5/thumbnails/54.jpg)
54
Reverse dot (RDB) blot hybridization for detection of 10 common β-thalassaemia mutations
![Page 55: Dr. Derakhshandeh, PhD Mutation Screening 2 Quantitative PCR and Dosage](https://reader031.vdocument.in/reader031/viewer/2022032203/56649e0c5503460f94af5ca8/html5/thumbnails/55.jpg)
55
-thalassemia Patients
![Page 56: Dr. Derakhshandeh, PhD Mutation Screening 2 Quantitative PCR and Dosage](https://reader031.vdocument.in/reader031/viewer/2022032203/56649e0c5503460f94af5ca8/html5/thumbnails/56.jpg)
56
Screening for causal mutations
• genomic DNA from patient blood samples
• reverse dot blot (RDB) • amplification refractory
mutation system-polymerase chain reaction (ARMSPCR)
• DNA sequencing
![Page 57: Dr. Derakhshandeh, PhD Mutation Screening 2 Quantitative PCR and Dosage](https://reader031.vdocument.in/reader031/viewer/2022032203/56649e0c5503460f94af5ca8/html5/thumbnails/57.jpg)
57
PCR from genomic DNA
720 bp
![Page 58: Dr. Derakhshandeh, PhD Mutation Screening 2 Quantitative PCR and Dosage](https://reader031.vdocument.in/reader031/viewer/2022032203/56649e0c5503460f94af5ca8/html5/thumbnails/58.jpg)
58
![Page 59: Dr. Derakhshandeh, PhD Mutation Screening 2 Quantitative PCR and Dosage](https://reader031.vdocument.in/reader031/viewer/2022032203/56649e0c5503460f94af5ca8/html5/thumbnails/59.jpg)
59
![Page 60: Dr. Derakhshandeh, PhD Mutation Screening 2 Quantitative PCR and Dosage](https://reader031.vdocument.in/reader031/viewer/2022032203/56649e0c5503460f94af5ca8/html5/thumbnails/60.jpg)
60
Strips
N M
1
2
3
4
5
6
7
8
9
1 2 3 4 5 6 7 8 9 10
![Page 61: Dr. Derakhshandeh, PhD Mutation Screening 2 Quantitative PCR and Dosage](https://reader031.vdocument.in/reader031/viewer/2022032203/56649e0c5503460f94af5ca8/html5/thumbnails/61.jpg)
61
The Blots
![Page 62: Dr. Derakhshandeh, PhD Mutation Screening 2 Quantitative PCR and Dosage](https://reader031.vdocument.in/reader031/viewer/2022032203/56649e0c5503460f94af5ca8/html5/thumbnails/62.jpg)
62
Comparison of different factors determining the efficiency of ARMS and reverse hybridization in beta thalassemia diagnosis
ARMS Reverse hybridization
Turnover time several days 6-8 hours
Equipment Expensive (large PCR machine, gel electrophoresis, photodocumentationsystem
Less expensive (small PCR machine, agarose gel, small shaking water bath)
Number of PCR reactions per sample
8-88 1
Documentation Requires documentation process after experiment
Self-documented
Technician time (number of patients: time in days)
1:1 10:1
Starting material Depending on the number of PCR reactions
0.5 μg genomic DNA for just one PCR reaction
Toxic materials Ethidium bromide (carcinogen)
None
![Page 63: Dr. Derakhshandeh, PhD Mutation Screening 2 Quantitative PCR and Dosage](https://reader031.vdocument.in/reader031/viewer/2022032203/56649e0c5503460f94af5ca8/html5/thumbnails/63.jpg)
63
In the late stages of muscular dystrophy, fat and connective tissue often replace muscle fibers.
![Page 64: Dr. Derakhshandeh, PhD Mutation Screening 2 Quantitative PCR and Dosage](https://reader031.vdocument.in/reader031/viewer/2022032203/56649e0c5503460f94af5ca8/html5/thumbnails/64.jpg)
64
![Page 65: Dr. Derakhshandeh, PhD Mutation Screening 2 Quantitative PCR and Dosage](https://reader031.vdocument.in/reader031/viewer/2022032203/56649e0c5503460f94af5ca8/html5/thumbnails/65.jpg)
65
DMD
![Page 66: Dr. Derakhshandeh, PhD Mutation Screening 2 Quantitative PCR and Dosage](https://reader031.vdocument.in/reader031/viewer/2022032203/56649e0c5503460f94af5ca8/html5/thumbnails/66.jpg)
66
Orthopaedic management of patients with Duchenne's muscular dystrophy
![Page 67: Dr. Derakhshandeh, PhD Mutation Screening 2 Quantitative PCR and Dosage](https://reader031.vdocument.in/reader031/viewer/2022032203/56649e0c5503460f94af5ca8/html5/thumbnails/67.jpg)
67~95% of deletions can be detected in males using multiplex PCR
L A B C D E F G H L
![Page 68: Dr. Derakhshandeh, PhD Mutation Screening 2 Quantitative PCR and Dosage](https://reader031.vdocument.in/reader031/viewer/2022032203/56649e0c5503460f94af5ca8/html5/thumbnails/68.jpg)
68
MAPH
•Detection of deletions/duplication mutations in Duchenne Muscular Dystrophy using: Multiplex Amplifiable Probe Hybridisation (MAPH)
![Page 69: Dr. Derakhshandeh, PhD Mutation Screening 2 Quantitative PCR and Dosage](https://reader031.vdocument.in/reader031/viewer/2022032203/56649e0c5503460f94af5ca8/html5/thumbnails/69.jpg)
69
MAPH• Although ~95% of deletions can be detected
in males using multiplex PCR• other methods must be used to determine
duplications, as well as the carrier status of females
• The most commonly applied methods are quantitative multiplex PCR and quantitative Southern blotting
• The drawback of quantitative multiplex PCR is that often not all mutations are examined
• meaning that small and rare mutations are missed
![Page 70: Dr. Derakhshandeh, PhD Mutation Screening 2 Quantitative PCR and Dosage](https://reader031.vdocument.in/reader031/viewer/2022032203/56649e0c5503460f94af5ca8/html5/thumbnails/70.jpg)
70
MAPH
• Using high-quality Southern blots it is possible to perform a quantitative analysis and detect duplications
• this technique is time consuming• it is difficult to exactly determine the
duplication • it can be difficult to detect duplications in
females and triplications will be missed
Armour et al (Nucl.Acids Res. 2000)
![Page 71: Dr. Derakhshandeh, PhD Mutation Screening 2 Quantitative PCR and Dosage](https://reader031.vdocument.in/reader031/viewer/2022032203/56649e0c5503460f94af5ca8/html5/thumbnails/71.jpg)
71
• system for analysing all 79 exons of the DMD gene for deletions and duplications
• MAPH is based on a quantitative PCR of short DNA probes recovered after hybridisation to immobilized genomic DNA
![Page 72: Dr. Derakhshandeh, PhD Mutation Screening 2 Quantitative PCR and Dosage](https://reader031.vdocument.in/reader031/viewer/2022032203/56649e0c5503460f94af5ca8/html5/thumbnails/72.jpg)
72
• 1 ug of denatured genomic DNA is spotted on a small nylon filter
• hybridized overnight in a solution containing one of the probe mixes
• Following stringent washing the next day the filter is placed in a PCR tube
• and a short PCR reaction is performed• This releases the specifically-bound
probes into the solution• An aliquot of this is transferred to a
second, quantitative PCR reaction